{"classes":[{"categories":[{"measurements":[{"comment":"Here \"NA\" indicates that upper limit of 95% CI was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"5.65","upperLimit":"NA","value":"8.34"},{"comment":"Here \"NA\" indicates that upper limit of 95% CI was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"11.27","upperLimit":"NA","value":"24.18"}]}],"title":"EQ-5D-5L: Visual Analogue Score"},{"categories":[{"measurements":[{"comment":"Here \"NA\" indicates that upper limit of 95% CI was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"8.15","upperLimit":"NA","value":"14.29"},{"comment":"Here \"NA\" indicates that upper limit of 95% CI was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"8.34","upperLimit":"NA","value":"24.11"}]}],"title":"EQ-5D-5L: Utility Score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"Time to worsening= time interval (months) from randomization to first observation of deterioration. EQ-5D-5L consists of a 5-item descriptive system and the EuroQol visual analog scale (EQ-5D VAS). EQ-5D-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Worsening is defined as a decrease of \\>= 7 points (on a 0-100 scale).\n\nEQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe participant's current health state. Responses for 5 dimensions are combined into a 5-digit number describing respondents health state that can be converted into a single index value or utility score (using the United Kingdom weights), ranging from -1 to 1, where lower scores indicate a worse health status. Worsening is defined as a decrease of \\>=0.08 points (on a 0-1 scale).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ibrutinib 420 milligrams (mg) orally once daily for 3 cycles (each cycle is of 28 days) followed by the combination of ibrutinib 420 mg and venetoclax 400 mg orally once daily for 12 cycles (including a 5-week venetoclax dose ramp up starting in cycle 4). Participants who subsequently developed independent review committee (IRC)-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment Arm A (Ibrutinib + Venetoclax)"},{"description":"Participants received chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight orally once daily on Days 1 and 15 of Cycles 1 to 6 in combination with obinutuzumab 1000 mgs intravenously (IV) once daily on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 to 6 (each cycle is of 28 days). Participants who subsequently developed IRC-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.","id":"OG001","title":"Treatment Arm B (Chlorambucil + Obinutuzumab)"}],"paramType":"MEDIAN","populationDescription":"The ITT analysis set included all randomized participants who were analyzed according to assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 2 years 10 months","title":"Time to Worsening as Measured by Using EuroQol 5 Dimension 5 Level Questionnaire (EQ-5D-5L)","type":"SECONDARY","unitOfMeasure":"Months"}